Ioannis Gounaris

Ioannis Gounaris

Company: Merck KGaA

Job title: Senior Medical Director Cluster Lead DNA Damage Response (DDR) Inhibitors, Global Clinical Development Oncology Group II

Seminars:

ATR Inhibitor-Based Combination Treatments in the Clinic: Biomarkers for Patient Selection 8:30 am

ATM remains the most studied biomarker for ATRi monotherapy activity and also for ATRi-DDRi combinations Explore how replication stress signatures represent an emerging biomarker, but not ready for prime time yet Learn how to optimally select patients for PARPi-ATRi in both the PARPi naïve and resistant settings remains a challengeRead more

day: Day Two

Breakfast Panel: Assessing the Situation: Improving Biomarker Characterization, Aiding Predictive Drug Development & Advancements in Addressing Patient Heterogeneity 8:00 am

Discussing target engagement and response biomarkers Exploring similarities between uses of biomarkers in pre-clinical vs clinical settings Debating the reliability of current biomarkers Is a global standard approach needed to evaluate biomarkers? How would we navigate this? Dissecting selecting alternative biomarkers for various populations How close to the route cause should we be going? (genomics,…Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.